YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Multiple myeloma (MM) remains incurable due to a lack of effective therapeutic targets.
• Aberrant N6-methyladenosine (m6A) RNA modification is implicated in various cancers, but its role in MM is underexplored.

Purpose of the Study:

• To investigate the role of m6A-related genes in multiple myeloma.
• To identify potential therapeutic targets for MM by analyzing m6A gene expression and patient outcomes.

Main Methods:

• Screening of m6A-related genes in MM patient cohorts.
• Analysis of YTHDF2 expression and its correlation with patient outcomes.
• In vitro and in vivo experiments to assess the impact of YTHDF2 on MM cell proliferation.
• m6A-RIP-seq, RIP-PCR, ChIP-seq, and PCR assays to elucidate downstream targets and molecular mechanisms.

Main Results:

• YTHDF2 expression is elevated in MM patients and associated with poor prognosis.
• Reduced YTHDF2 expression inhibits MM cell proliferation, while increased expression promotes it.
• YTHDF2 targets STAT5A mRNA for degradation, and STAT5A suppresses MM proliferation by inhibiting the MAP2K2/ERK pathway.

Conclusions:

• The YTHDF2/STAT5A/MAP2K2/p-ERK axis is crucial for MM cell proliferation.
• Targeting YTHDF2 represents a promising therapeutic strategy for multiple myeloma.